All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
To help navigate the exciting content being presented at the European Hematology Association 2024 Hybrid Congress, the AML Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in AML.
S130 |
14:45–15:00 |
Erin Hertlein |
|
S131 |
15:00–15:15 |
Ibrahim Aldoss |
|
S132 |
15:15–15:30 |
Naval Daver |
|
S133 |
15:30–15:45 |
Andrew H. Wei |
|
S134 |
15:45–16:00 |
Joshua Zeidner |
S135 |
11:30–11:45 |
Leo Ruhnke |
|
S136 |
11:45–12:00 |
FLAG-IDA + venetoclax (VEN) in newly diagnosed (ND) or relapsed/refractory (RR) AML |
Wei-Ying Jen |
S138 |
12:15–12:30 |
Naval Daver |
|
S139 |
12:30–12:45 |
Alex Bataller |
|
S102 |
15:15–15:30 |
Uwe Platzbecker |
|
S141 |
16:45–17:00 |
Maria Teresa Voso |
|
S142 |
17:00–17:15 |
Mikkael A. Sekeres |
|
S144 |
17:30–17:45 |
Jorge Cortes |
|
S265 |
16:30–16:45 |
Anne Sophie Kubasch |
LB3444 |
11:00–11:15 |
Stine Ulrik Mikkelsen |
|
S146 |
11:45–12:00 |
Sylvain Garciaz |
|
S148 |
12:15–12:30 |
Alberto Hernandez-Sanchez |
|
S149 |
12:30–12:45 |
Christian Récher |
P536 |
Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia study |
Jorge Cortes |
P540 |
Neerav Shukla |
|
P560 |
Andrew H. Wei |
|
P561 |
Andrius Žučenka |
|
P565 |
Gautam Borthakur |
|
P600 |
Dominik Chraniuk |
|
P603 |
Tapan Kadia |
|
P623 |
Ahmad Ibrahim |
|
P571 |
Christian Récher |
|
P573 |
Elisabetta Todisco |
|
P1377 |
James M Foran |
|
P1786 |
Vera Troitskaya |
|
P1792 |
Rithin Nedumannil |
|
P1805 |
Brian Leber |
|
P1810 |
Joana Infante |
|
P1818 |
The role of allo-HSCT in AML CR1 patients with MRD negativity after the first induction course |
Elena Parovichnikova |
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox